Drugs / Henggliflozin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06818851 | Jul 2025 → Dec 2027 expected | type 2 diabetes mellitus | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05966792 | Nov 2023 → Jun 2025 | polycystic ovary syndrome | Shanghai 10th People's Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | henggliflozin | “Intervention with henggliflozin (10mg qd) for 6 months” NCT05966792 ↗ |
| Action | Inhibit | “SGLT2 inhibitor Henggliflozin works to improve glucose variability in type 2 diabetes” NCT06818851 ↗ |
| Route | Oral | “Henggliflozin 10 mg or a placebo once daily by oral administration for up to 16 weeks.” NCT06818851 ↗ |